Dbv Technologies S.a.
A French biopharmaceutical company that develops Viaskin, a skin-patch treatment for food allergies, with its lead product targeting peanut allergy. Founded in 2003 as a spin-off from France's national medical research institute INSERM and based near Paris, the company builds on the idea that allergy immunotherapy can be delivered through the skin instead of needles. Its name comes from the initials of its two physician founders, who pioneered the patch approach.
American Depositary Shares (each representing ordinary shares), listed on Nasdaq Global Select Market
Sold 3.37M
Granted 44.0K · Sold 8.7K
Granted 32.0K
Granted 55.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bpifrance Investissement S.A.S. +4 co-filersMember of 10% owner group · 3 transactions | — | 7.53M | — | — | 3.37M |
| Mohideen PharisChief Medical Officer · 4 transactions | +32.2% | 145.0K | 44.0K | — | 8.7K |
| Boucinha VirginieChief Financial Officer · 1 transaction | +84.2% | 70.0K | 32.0K | — | — |
| Trapp Kevin MichaelChief Commercial Officer · 1 transaction | — | 55.0K | 55.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -3.38M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.